117 related articles for article (PubMed ID: 38677731)
1. Comparison of Prognostic Scores in Early Phase Clinical Trials: A 10-year Single Centre Australian Experience.
Childs S; Nindra U; Yoon R; Haider S; Hong M; Roohullah A; Cooper A; Wilkinson K; Chua W; Pal A
Anticancer Res; 2024 May; 44(5):2095-2102. PubMed ID: 38677731
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer.
Ma LX; Espin-Garcia O; Bach Y; Aoyama H; Allen MJ; Wang X; Darling GE; Yeung J; Swallow CJ; Brar S; Veit-Haibach P; Kalimuthu S; Wong R; Chen EX; O'Kane GM; Jang RW; Elimova E
Oncologist; 2023 Mar; 28(3):214-219. PubMed ID: 36378560
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
4. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
[TBL] [Abstract][Full Text] [Related]
5. Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center.
Al Darazi G; Martin E; Delord JP; Korakis I; Betrian S; Estrabaut M; Poublanc M; Gomez-Roca C; Filleron T
Int J Cancer; 2021 May; 148(10):2502-2511. PubMed ID: 33231298
[TBL] [Abstract][Full Text] [Related]
6. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
7. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
Hahn AW; Alhalabi O; Msaouel P; Meric-Bernstam F; Naing A; Jonasch E; Piha-Paul S; Hong D; Pant S; Yap T; Campbell E; Le H; Tannir NM; Roszik J; Subbiah V
ESMO Open; 2020 Nov; 5(6):e001073. PubMed ID: 33229506
[TBL] [Abstract][Full Text] [Related]
8. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
9. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden.
Korolewicz JA; Scheiner B; Fulgenzi CAM; D'Alessio A; Cortellini A; Pascual C; Mehan A; Partridge S; Gujral DM; Mohammed W; Mohammed O; Grzesiak A; Booker L; Cleator S; Pokrovska T; Saleem W; Rackie J; Needham Y; Krell J; McNeish I; Tookman L; Park WE; Asif M; Evans JS; Pinato DJ
Chemotherapy; 2024 Apr; ():1-7. PubMed ID: 38679017
[TBL] [Abstract][Full Text] [Related]
10. Time toxicity associated with early phase clinical trial participation.
Nindra U; Shivasabesan G; Childs S; Yoon R; Haider S; Hong M; Cooper A; Roohullah A; Wilkinson K; Pal A; Chua W
ESMO Open; 2023 Dec; 8(6):102046. PubMed ID: 37979324
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F; Bautista FJ; Jiménez I; Hladun-Álvaro R; Giraud C; Bergamaschi L; Dandapani M; Aerts I; Doz F; Frappaz D; Casanova M; Morland B; Hargrave DR; Marshall LV; Vassal G; Pearson AD; Geoerger B; Moreno L
Eur J Cancer; 2016 Nov; 67():130-140. PubMed ID: 27662616
[TBL] [Abstract][Full Text] [Related]
12. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
14. [Early phase trials at the "Institut de cancérologie de l'Ouest": Clinical outcome and validation of prognostic scores].
Greilsamer C; Campion L; Cabart M; Gourmelon C; Senellart H; Bennouna J
Bull Cancer; 2018 Oct; 105(10):896-906. PubMed ID: 30348261
[TBL] [Abstract][Full Text] [Related]
15. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
[TBL] [Abstract][Full Text] [Related]
17. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Wheler J; Tsimberidou AM; Hong D; Naing A; Falchook G; Piha-Paul S; Fu S; Moulder S; Stephen B; Wen S; Kurzrock R
Clin Cancer Res; 2012 May; 18(10):2922-9. PubMed ID: 22452943
[TBL] [Abstract][Full Text] [Related]
18. Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: A propensity score matching retrospective cohort study.
Li SJ; Zhao L; Wang HY; Zhou HN; Ju J; Du H; Che GW
Int J Surg; 2020 Dec; 84():25-40. PubMed ID: 33086147
[TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
20. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
Ediebah DE; Quinten C; Coens C; Ringash J; Dancey J; Zikos E; Gotay C; Brundage M; Tu D; Flechtner HH; Greimel E; Reeve BB; Taphoorn M; Reijneveld J; Dirven L; Bottomley A;
Cancer; 2018 Aug; 124(16):3409-3416. PubMed ID: 29905936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
